Table 1.
Firstline therapy recommended by National Comprehensive Cancer Network (NCCN) guideline 2020.4.
| Protocol | Efficacy | Median OS (95% CI) | 5-Year OS | Median PFS (95% CI) | 5-Year PFS | Reference |
|---|---|---|---|---|---|---|
| nivolumab monotherapy | 43.7% | 36.9 M | 44.0% | 11.5 M | 29.0% | [7] |
| pembtolizumab monotherapy | 36.0% | 32.7 M | 38.7% | 8.4 M | 23.0% (4-year) | [38] |
| N + I combination therapy | 57.6% | 60 M | 52.0% | 6.9 M | 36.0% | [7] |
| D + T combination therapy | 68.0% | 25.9 M (22.6–31.5) | 34.0% | 11.1 M (9.5–12.8) | 19.0% | [34] |
| V + C combination therapy | 70.0% | 22.3 months (20·3–N.E.) | 12.3 M (9.5–13.4) | [33] | ||
| E + B combination therapy | 64.0% | 33.6 M (24.4–39.2) | 14.9 M (11.0–20.2) | [32] | ||
| A + V + C combination therapy | 66.3% | N.E. (2 years) | 16.1 M (11.3–18.5) | [39] |
N.E.: not estimable; N + I: nivolumab + ipilimumab; D + T: dabrafenib + trametinib; V + C: vemurafenib + cobimetinib; E + B: encorafenib + binimetinib; A + V + C: atezolizumab + V + C.